$PEN

Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake

Vanguard Capital Management has reported a beneficial ownership of 1,990,629 shares in Penumbra Inc. (NYSE: PEN), which represents a 5.07% stake. This information is disclosed in a Schedule 13G SEC filing, indicating Vanguard's passive investment intentions. The filing details Vanguard's sole dispositive power over all 1.99 million shares and sole voting power over 296,141 shares, signed by Ashley Grim.

Original reporting
Published May 1, 2026, 2:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 1, 2026, 2:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake — source image
Decision brief

The 30-second read

$PENNeutralLow
01

Why it matters

This disclosure signals institutional interest but does not imply active trading or strategic shifts.

02

Market read

The news has limited immediate trading impact; primarily relevant for understanding institutional ownership patterns.

03

What to watch

Passive ownership disclosures are routine; they do not necessarily indicate future trading intentions or market movements.

Relevance 6/10Timing: low

Background

Vanguard Capital Management filed a Schedule 13G indicating passive ownership of 1.99 million shares of Penumbra Inc., representing 5.07% of the company.

Company-level read

Ticker impact

$PENNeutralMedium confidence
Context

The news pertains to Vanguard Capital Management's passive stake in Penumbra Inc., indicating institutional ownership but limited immediate trading impact.

Expected impact

Minimal short-term price movement expected; long-term implications depend on Vanguard's future actions.

Evidence & confidence

Passive ownership disclosures typically have limited immediate market impact unless accompanied by active trading or strategic moves.

Market effects

Limited; the focus is on institutional ownership rather than sector-wide developments.

Minimal; the news is specific to US-listed Penumbra Inc.

negligible; no broader global implications.

Counterpoint

Some investors might interpret Vanguard's passive stake as a sign of confidence, potentially supporting the stock.

Key entities

  • Vanguard Capital Management

    A major asset management firm making a passive investment in Penumbra Inc.

  • Penumbra Inc.

    A healthcare company specializing in neuro and peripheral vascular devices.

Related articles

$BSXHighAI 8/10

Boston Scientific Climbs 2% After Steep Decline, Regains 38% of Thursday’s Loss

Boston Scientific (BSX) rose 2.03% to $50.37 on Friday, recovering 38% of Thursday's loss. The stock's weekly decline was 2.82%. Analysts forecast 24.46% upside, with 26 of 31 rating it Buy or Strong Buy. The company reported Q2 sales of $5.442 billion, up 7.5%, but lowered full-year EPS guidance. It plans a $14.5 billion acquisition of Penumbra (PEN).

$PENMed

Panoro Energy to Acquire Côte

Panoro Energy ASA will acquire a 9.09% interest in Block CI-27 offshore Côte d’Ivoire from DNO ASA for $80M. The asset has 3,287 boepd production and 9.4 MMboe reserves. Panoro aims to boost production and reserves, financing the deal with equity and debt.

$PENMed

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. • Revenue of

$PENMedAI 8/10

FDA clears Thunderbolt, computer-assisted thrombectomy device for ischemic stroke

Penumbra said the FDA cleared its Thunderbolt computer-assisted vacuum thrombectomy device for acute ischemic stroke, aimed at distal occlusions. Thunderbolt uses modulated aspiration with standard aspiration to help remove clots more completely. IDE study results will be presented in July, and Penumbra also reported a CE Mark and starting the Forward study.